USRE37002E - Lipid-dispersed solution, production thereof and use in determining lipid levels - Google Patents

Lipid-dispersed solution, production thereof and use in determining lipid levels Download PDF

Info

Publication number
USRE37002E
USRE37002E US09/327,019 US32701999A USRE37002E US RE37002 E USRE37002 E US RE37002E US 32701999 A US32701999 A US 32701999A US RE37002 E USRE37002 E US RE37002E
Authority
US
United States
Prior art keywords
lipid
solution
cholesterol
bile acid
dispersed solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/327,019
Inventor
Tomohiro Yamamoto
Toshihiko Yoshioka
Shiro Nankai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panasonic Holdings Corp
Original Assignee
Matsushita Electric Industrial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matsushita Electric Industrial Co Ltd filed Critical Matsushita Electric Industrial Co Ltd
Priority to US09/327,019 priority Critical patent/USRE37002E/en
Application granted granted Critical
Publication of USRE37002E publication Critical patent/USRE37002E/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
    • Y10S516/928—Mixing combined with non-mixing operation or step, successively or simultaneously, e.g. heating, cooling, ph change, ageing, milling
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control

Definitions

  • the present invention relates to an aqueous dispersed solution as a standard solution for determining the content of lipids, and a process for producing the same.
  • lipid levels in a body fluid has rapidly come into wide use with the recent development of an enzymatic determination process, and its utility in the field of clinical diagnosis has been increasing. Therefore, a proper standard solution for determination of lipid levels is required.
  • the lipid in these standard solutions differs in the existing state and fluid property from the lipid in the humor such as serum. This causes a great difference in reactivity between the standard solution and the body fluid (e.g., serum) as a specimen, which results in error in determined value.
  • a dispersed solution shows excellent characteristics as a cholesterol standard solution, which is obtained by evaporating an organic solvent from a mixture prepared by adding cholesterol, lecithin, a surfactant and a neutral lipid, and/or a cholesterol ester in the organic solvent in a specific range of the concentration ratio, swelling the resultant thin-film like mixture with water or a buffer solution heated at a temperature higher than a phase transition temperature of the lecithin, and then dispersing the solution by ultrasonic irradiation.
  • a cholesterol standard solution which is obtained by evaporating an organic solvent from a mixture prepared by adding cholesterol, lecithin, a surfactant and a neutral lipid, and/or a cholesterol ester in the organic solvent in a specific range of the concentration ratio, swelling the resultant thin-film like mixture with water or a buffer solution heated at a temperature higher than a phase transition temperature of the lecithin, and then dispersing the solution by ultrasonic irradiation.
  • the present invention provides a lipid-dispersed solution comprising a bile acid or a salt thereof, and a phospholipid, cholesterol and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid as the lipids, and water or an aqueous solvent as a dispersing medium, the bile acid or the salt thereof and the lipids being dispersed in the water or aqueous solvent.
  • the present invention also provides a process for producing a lipid-dispersed solution, which comprises the steps of dissolving bile acid or a salt thereof and lipids in an organic solvent, evaporating the organic solvent from the resultant solution, and adding water or an aqueous solvent to the residual solid content to apply a physical shear force.
  • the step of applying the physical shear force is conducted under a deoxygenated atmosphere.
  • the step of evaporating the organic solvent is conducted at a temperature where the bile acid or salt thereof and the lipids can be dissolved in the organic solvent.
  • the lipids comprise a phospholipid, cholesterol, and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid.
  • cholesterol linoleate is used as the cholesterol and cholesterol ester
  • lecithin is used as the phospholipid
  • sodium taurodeoxycholate is used as the bile acid salt
  • tristearin is used as the neutral lipid.
  • a weight ratio of the sum of the cholesterol and cholesterol ester to the lecithin is from 1:1 to 1:4
  • a weight ratio of bile acid salt to the lecithin is from 1:1 to 1:20
  • a weight ratio of the neutral lipid to the lecithin is from 1:10 to 1:5
  • a concentration of the lecithin is not more than 1,000 mg/dl when the lecithin is finally dispersed in water or buffer.
  • the cholesterol standard solution prepared by the above process has a dispersion form and a particle size, which are similar to those of serum lipids, and can provide a dispersed solution having a concentration of the sum of the cholesterol and cholesterol ester of about less than 1,000 mg/dl.
  • the cholesterol-dispersed solution thus prepared is extremely stable and can be stored for a long period of time.
  • the step of evaporating 2-propanol to form the thin film may be conducted by spraying an inert gas (e.g., nitrogen or argon) to the above solution in place of vacuum evaporation by a rotary evaporator.
  • an inert gas e.g., nitrogen or argon
  • oxidation of the phospholipids and neutral lipids in the step of forming the thin film can be prevented by evaporating the solvent under deoxygenated atmosphere.
  • Water or phosphate buffer as the aqueous solvent heated to the temperature higher than a phase transition temperature of phosphatidyl choline was added to the glass container in which the thin film was formed on the inner wall and the thin film was swollen. Then, an ultrasonic wave was irradiated by an ultrasonic crusher in order to apply a physical shear force and the above thin film was dispersed in water or phosphate buffer. A diameter of dispersed lipid particles varied depending on the output and irradiation time of the ultrasonic wave. Finally, lipid particles having a diameter of about 50 nm was obtained.
  • a French press can also be used in place of the ultrasonic crusher.
  • a cholesterol standard solution containing ester type cholesterol such as cholesterol linoleate and a neutral lipid such as tristearin was obtained by adding water or a buffer solution to the thin film formed by the above process and dispersing in the same manner as that described in Example 1.
  • ester type cholesterol and a neutral lipid which have a strong hydrophobic nature, exist in the central part of the particles, and phospholipid and cholesterol, a hydrophilic side chain of which exists outside, form the surface of the lipid particles so as to cover the ester type cholesterol and neutral lipid.
  • Such a form is similar to that of lipids in the blood.
  • phosphatidyl choline is used as the phospholipid
  • cholesterol linoleate is used as the cholesterol ester
  • tristearin which is one sort of triglycerides is used as the neutral lipid
  • sodium cholate and sodium taurodeoxycholate are used as the bile acid salt
  • taurodeoxycholic acid is used as the bile acid, but they are not limited thereto.
  • phospholipid for example, phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol, phosphatidic acid, sphingomyelin and lysolecithin can be used alone or in combination.
  • cholic acid for example, cholic acid, taurodeoxycholic acid, taurocholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid and a sodium salt thereof can be used alone or in combination.
  • neutral lipid for example, triglycerides (e.g., tristearin, tripalmitin, etc.), of which constituent fatty acid has about 9 to 17 carbon atoms, can be used.
  • cholesterol ester for example, those having a fatty side chain, of which hydrocarbon group has 18 or less carbon atoms, can be used.
  • the effect of the present invention is not damaged even if a bile acid is used in place of the bile acid salt in the Example which uses the bile acid salt, and the bile acid salt is used in place of the bile acid in the Examples which use the bile acid.
  • organic solvent for dissolving the lipid so as to form the thin film 2-propanol is used, but there can be used any organic solvent which can dissolve the phospholipid, cholesterol, bile acid or bile acid salt, cholesterol ester and neutral lipid, such as alcohol (e.g., 2-propanol, ethanol, methanol, etc.) diethyl ether, isopropyl ether, chloroform, dichloromethane, etc.
  • alcohol e.g., 2-propanol, ethanol, methanol, etc.
  • diethyl ether diethyl ether
  • isopropyl ether diethyl ether
  • chloroform dichloromethane, etc.
  • the present invention there can be easily obtained a dispersed solution having the dispersion form and particle size, which are similar to those of serum lipids, and a high concentration of the sum total of the cholesterol and cholesterol ester, such as about less than 1,000 mg/dl.
  • the cholesterol-dispersed solution thus prepared is extremely stable and can be stored at room temperature for a long period of time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

.[.There is disclosed an aqueous dispersed solution as a standard solution for determining lipid levels, having a dispersion form and a particle size, which are similar to those of serum lipids. A lipid-dispersed solution is obtained by evaporating an organic solvent from a mixture prepared by adding cholesterol, a phospholipid, a bile acid or bile acid salt, and a neutral lipid and/or a cholesterol ester in the organic solvent, swelling the resultant thin-film like mixture with water or buffer heated at a temperature higher than a phase transition temperature of the lecithin, and then dispersing the solution by a physical shear force. There can be easily obtained a solution having a cholesterol concentration of about less than 1,000 mg/dl, which is extremely stable and can be stored for a long period of time..]. .Iadd.There is disclosed an aqueous dispersed solution as a standard solution for determining lipid levels, having a dispersion form and a particle size, which are similar to those of serum lipids. A lipid-dispersed solution is obtained by evaporating an organic solvent from a mixture prepared by adding cholesterol, a phospholipid, a bile acid or bile acid salt, and a neutral lipid and/or a cholesterol ester in the organic solvent, swelling the resultant thin-film like mixture with water or buffer heated at a temperature higher than a phase transition temperature of the lecithin, and then dispersing the solution by a physical shear force. These can be easily obtained a solution having a cholesterol concentration of about less than 1,000 mg/dl, which is extremely stable and can be stored for a long period of time. The lipid dispersed solution is used as a standard solution in calibrating a device for performing enzymatic lipid level determination, and the calibrated device is used to determine the lipid level (e.g. cholesterol) in a solution.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an aqueous dispersed solution as a standard solution for determining the content of lipids, and a process for producing the same.
2. Description of the Prior Art
Determination of lipid levels in a body fluid, particularly determination of cholesterol levels, has rapidly come into wide use with the recent development of an enzymatic determination process, and its utility in the field of clinical diagnosis has been increasing. Therefore, a proper standard solution for determination of lipid levels is required. However, it is essentially difficult to dissolve lipids in water and, therefore, those dissolved in an organic solvent are exclusively used. For this, the lipid in these standard solutions differs in the existing state and fluid property from the lipid in the humor such as serum. This causes a great difference in reactivity between the standard solution and the body fluid (e.g., serum) as a specimen, which results in error in determined value.
Therefore, human- or animal-derived serum or purified lipoprotein cholesterol has been used as the standard solution. The process for purifying lipoprotein cholesterol is described, for example, in Japanese Laid-Open Patent Publication No. 56-101555. However, in the process using sera, it is difficult to obtain sera at a cheap price and, at the same time, there is a fear of an influence of unknown impurities on the determined value. The process for purifying lipoproteins has also a problem of complexity.
In order to improve these drawbacks, those which are solubilized in water with a surfactant have been used as the standard solution. However, a large amount of the surfactant is required for the solubilization of lipids in water. Therefore, the viscosity of the solution prepared by this process becomes high and its handling is sometimes difficult.
In order to solve this problem, it is suggested to use a mixture of a surfactant and lipids, which are different in HLB value (e.g., Japanese Laid-Open Patent Publication No. 57-84356). However, regarding the solution obtained by this process, the enzymatic reaction is sometimes inhibited by the surfactant present in the solution in the above enzymatic determination process. Since the lipid dispersion form is different from that in serum, the solution is not sometimes suitable as the standard solution according to the determination process.
As described above, various processes for stably dissolving or dispersing lipids in a simple procedure have been studied.
However, the fact that the dispersion form of lipids is largely different from that in serum as described above sometimes becomes a problem which hinders the use of the solution as the standard solution for calibrating a device. Taking this point into consideration, a process for dispersing lipids using the surfactant is also used. However, there is a problem that a high concentration of cholesterol, which is generated physiologically, can not be dispersed stably when a surfactant may be used.
SUMMARY OF THE INVENTION
The present inventors have studied intensively in order to solve the above problems. As a result, it is found that a dispersed solution shows excellent characteristics as a cholesterol standard solution, which is obtained by evaporating an organic solvent from a mixture prepared by adding cholesterol, lecithin, a surfactant and a neutral lipid, and/or a cholesterol ester in the organic solvent in a specific range of the concentration ratio, swelling the resultant thin-film like mixture with water or a buffer solution heated at a temperature higher than a phase transition temperature of the lecithin, and then dispersing the solution by ultrasonic irradiation.
The present invention provides a lipid-dispersed solution comprising a bile acid or a salt thereof, and a phospholipid, cholesterol and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid as the lipids, and water or an aqueous solvent as a dispersing medium, the bile acid or the salt thereof and the lipids being dispersed in the water or aqueous solvent.
The present invention also provides a process for producing a lipid-dispersed solution, which comprises the steps of dissolving bile acid or a salt thereof and lipids in an organic solvent, evaporating the organic solvent from the resultant solution, and adding water or an aqueous solvent to the residual solid content to apply a physical shear force.
It is preferred that the step of applying the physical shear force is conducted under a deoxygenated atmosphere.
In addition, it is preferred that the step of evaporating the organic solvent is conducted at a temperature where the bile acid or salt thereof and the lipids can be dissolved in the organic solvent.
The lipids comprise a phospholipid, cholesterol, and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid.
In one embodiment of the present invention, it is preferred that cholesterol linoleate is used as the cholesterol and cholesterol ester, lecithin is used as the phospholipid, sodium taurodeoxycholate is used as the bile acid salt, and tristearin is used as the neutral lipid. It is also preferred that a weight ratio of the sum of the cholesterol and cholesterol ester to the lecithin is from 1:1 to 1:4, a weight ratio of bile acid salt to the lecithin is from 1:1 to 1:20, a weight ratio of the neutral lipid to the lecithin is from 1:10 to 1:5, and a concentration of the lecithin is not more than 1,000 mg/dl when the lecithin is finally dispersed in water or buffer.
The cholesterol standard solution prepared by the above process has a dispersion form and a particle size, which are similar to those of serum lipids, and can provide a dispersed solution having a concentration of the sum of the cholesterol and cholesterol ester of about less than 1,000 mg/dl. The cholesterol-dispersed solution thus prepared is extremely stable and can be stored for a long period of time.
While the novel features of the invention are set forth particularly in the appended claims, the invention, both as to organization and content, will be better understood and appreciated, along with other objects and features thereof, from the following detailed description taken in conjunction with the drawings.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The following Examples further illustrate the present invention in detail but are not construed to limit the scope thereof.
EXAMPLE 1
Sixty (60) mg of cholesterol, 90 mg of phosphatidyl choline as the phospholipid, 18 mg of tristearin as the neutral lipid and 4.5 mg of sodium cholate as the bile acid salt were dissolved in 1 ml of 2-propanol as the organic solvent. The resultant solution was charged in a glass container such as a test tube which was rotated using a rotary evaporator, and then 2-propanol was evaporated under reduced pressure. Thus, a thin film as a homogeneous mixture of cholesterol, phosphatidyl choline, tristearin and sodium cholate was formed on the inner wall of the glass container.
The step of evaporating 2-propanol to form the thin film may be conducted by spraying an inert gas (e.g., nitrogen or argon) to the above solution in place of vacuum evaporation by a rotary evaporator. In such way, oxidation of the phospholipids and neutral lipids in the step of forming the thin film can be prevented by evaporating the solvent under deoxygenated atmosphere.
Water or phosphate buffer as the aqueous solvent heated to the temperature higher than a phase transition temperature of phosphatidyl choline was added to the glass container in which the thin film was formed on the inner wall and the thin film was swollen. Then, an ultrasonic wave was irradiated by an ultrasonic crusher in order to apply a physical shear force and the above thin film was dispersed in water or phosphate buffer. A diameter of dispersed lipid particles varied depending on the output and irradiation time of the ultrasonic wave. Finally, lipid particles having a diameter of about 50 nm was obtained.
As the process for applying the physical shear force so as to disperse the thin film, a French press can also be used in place of the ultrasonic crusher.
In the present Example, sodium cholate as the surfactant is also dissolved in 2-propanol so that it can be contained uniformly in the thin film. When sodium cholate is not added to the 2-propanol solution and is added in the step of swelling and dispersing the thin film, a solution having a desirable particle size can not be obtained.
EXAMPLE 2
Fifteen (15) mg of cholesterol, 90 mg of phosphatidyl choline as the phospholipid, 45 mg of cholesterol linoleate as the cholesterol ester and 4.5 mg of deoxycholic acid as the bile acid were dissolved in 1 ml of 2-propanol as the organic solvent. A cholesterol standard solution containing ester type cholesterol such as cholesterol linoleate was obtained by charging the resultant solution in a glass container such as a test tube and dispersing the solution in water or an aqueous solvent in the same manner as that described in Example 1.
EXAMPLE 3
Fifteen (15) mg of cholesterol, 90 mg of phosphatidyl choline as the phospholipid, 45 mg of cholesterol linoleate as the cholesterol ester, 18 mg of tristearin as the neutral lipid and 4.5 mg of sodium taurodeoxycholate as the bile acid salt were dissolved in 1 ml of 2-propanol as the organic solvent. The resultant solution was charged in a glass container such as a test tube which was rotated using a rotary evaporator, and then 2-propanol was evaporated under reduced pressure. Thus, a thin film as a homogeneous mixture of cholesterol, phosphatidyl choline, tristearin and sodium cholate was formed on the inner wall of the glass container.
It is necessary to heat the glass container to about 60° C. when the solvent is evaporated to form a thin film. When the temperature is about room temperature, the above solution rapidly forms a white precipitate. The temperature at the time of forming the thin film must be the temperature at which the cholesterol, phospholipid, cholesterol ester, neutral lipid and bile acid salt, as the solute, can exist without depositing and precipitating. Accordingly, it is necessary to pay attention to the fact that the optimum temperature for forming the thin film varies depending on the combination and amount of the solutes.
A cholesterol standard solution containing ester type cholesterol such as cholesterol linoleate and a neutral lipid such as tristearin was obtained by adding water or a buffer solution to the thin film formed by the above process and dispersing in the same manner as that described in Example 1.
Regarding the form of lipid particles of the cholesterol standard solution obtained by this process, ester type cholesterol and a neutral lipid, which have a strong hydrophobic nature, exist in the central part of the particles, and phospholipid and cholesterol, a hydrophilic side chain of which exists outside, form the surface of the lipid particles so as to cover the ester type cholesterol and neutral lipid. Such a form is similar to that of lipids in the blood.
In the above Examples, phosphatidyl choline is used as the phospholipid, cholesterol linoleate is used as the cholesterol ester, tristearin which is one sort of triglycerides is used as the neutral lipid, sodium cholate and sodium taurodeoxycholate are used as the bile acid salt, and taurodeoxycholic acid is used as the bile acid, but they are not limited thereto.
As the phospholipid, for example, phosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol, phosphatidic acid, sphingomyelin and lysolecithin can be used alone or in combination.
As the bile acid or bile acid salt, for example, cholic acid, taurodeoxycholic acid, taurocholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid and a sodium salt thereof can be used alone or in combination.
As the neutral lipid, for example, triglycerides (e.g., tristearin, tripalmitin, etc.), of which constituent fatty acid has about 9 to 17 carbon atoms, can be used. As the cholesterol ester, for example, those having a fatty side chain, of which hydrocarbon group has 18 or less carbon atoms, can be used.
The effect of the present invention is not damaged even if a bile acid is used in place of the bile acid salt in the Example which uses the bile acid salt, and the bile acid salt is used in place of the bile acid in the Examples which use the bile acid.
As the organic solvent for dissolving the lipid so as to form the thin film, 2-propanol is used, but there can be used any organic solvent which can dissolve the phospholipid, cholesterol, bile acid or bile acid salt, cholesterol ester and neutral lipid, such as alcohol (e.g., 2-propanol, ethanol, methanol, etc.) diethyl ether, isopropyl ether, chloroform, dichloromethane, etc.
As described above, according to the present invention, there can be easily obtained a dispersed solution having the dispersion form and particle size, which are similar to those of serum lipids, and a high concentration of the sum total of the cholesterol and cholesterol ester, such as about less than 1,000 mg/dl. In addition, the cholesterol-dispersed solution thus prepared is extremely stable and can be stored at room temperature for a long period of time.
Although the present invention has been described in terms of the presently preferred embodiments, it is to be understood that such disclosure is not to be interpreted as limiting. Various alterations and modifications will no doubt become apparent to those skilled in the art to which the present invention pertains, after having read the above disclosure. Accordingly, it is intended that the appended claims be interpreted as covering all alterations and modifications as fall within the true spirit and scope of the invention.

Claims (5)

What is claimed is:
1. A process for producing a lipid-dispersed solution, which comprises the steps of dissolving a bile acid or a salt thereof and lipids in an organic solvent, wherein the lipids comprise a phospholipid, cholesterol and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid, evaporating the organic solvent from the resultant solution at a temperature where the bile acid or the salt thereof and the lipids can be dissolved in the organic solvent, adding water or an aqueous solvent to the residual solid content, and applying a physical shear force.
2. The process for producing a lipid-dispersed solution in accordance with claim 1, wherein the step of applying the physical shear force is a step of irradiating with an ultrasonic wave.
3. The process for producing a lipid-dispersed solution in accordance with claim 1, wherein the step of evaporating the organic solvent is conducted under a deoxygenated atmosphere.
4. The process for producing a lipid-dispersed solution in accordance with claim 1, wherein a weight ratio of a sum of cholesterol and cholesterol ester to phospholipid is from 1:1 to 1:4, a weight ratio of bile acid salt to phospholipid is from 1:1 to 1:20, and a weight ratio of neutral lipid to phospholipid is from 1:10 to 1:5. .Iadd.5. A method for determination of lipid levels using a lipid-dispersed solution as a standard, comprising (1) providing a lipid-dispersed solution comprising a bile acid or a salt thereof; a phospholipid, cholesterol, and at least one member selected from the group consisting of a cholesterol ester and a neutral lipid as the lipids; and water or an aqueous solvent as a dispersing medium, said bile acid or salt thereof and said lipids being dispersed in said water or aqueous solvent, (2) calibrating a device for performing enzymatic lipid level determination using said lipid-dispersed solution as a standard solution, and (3) using said device to determine the lipid level of a solution..Iaddend..Iadd.6. The method according to claim 5, wherein the lipid levels to be determined are those of a bodily fluid..Iaddend..Iadd.7. The method according to claim 6, wherein the bodily fluid lipid level to be determined is a cholesterol level..Iaddend..Iadd.8. The method according to claim 5, wherein the phospholipid is lecithin and wherein a weight ratio of the sum of the cholesterol and cholesterol ester to the lecithin is from 1:1 to 1:4, a weight ratio of the bile acid salt to the lecithin is from 1:1 to 1:20, a weight ratio of the neutral lipid to the lecithin is from 1:10 to 1:15, and a concentration of the lecithin is not more than 1,000
mg/dl..Iaddend..Iadd.9. The method of claim 5, wherein the concentration of said bile acid or salt thereof in said lipid-dispersed solution is from 50 to 1000 mg/dl..Iaddend.
US09/327,019 1995-05-24 1999-06-07 Lipid-dispersed solution, production thereof and use in determining lipid levels Expired - Fee Related USRE37002E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/327,019 USRE37002E (en) 1995-05-24 1999-06-07 Lipid-dispersed solution, production thereof and use in determining lipid levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP12484795 1995-05-24
JP7-124847 1995-05-24
US08/641,765 US5759445A (en) 1995-05-24 1996-05-02 Lipid-dispersed solution and process for producing the same
US09/327,019 USRE37002E (en) 1995-05-24 1999-06-07 Lipid-dispersed solution, production thereof and use in determining lipid levels

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/641,765 Reissue US5759445A (en) 1995-05-24 1996-05-02 Lipid-dispersed solution and process for producing the same

Publications (1)

Publication Number Publication Date
USRE37002E true USRE37002E (en) 2000-12-26

Family

ID=14895576

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/641,765 Ceased US5759445A (en) 1995-05-24 1996-05-02 Lipid-dispersed solution and process for producing the same
US09/327,019 Expired - Fee Related USRE37002E (en) 1995-05-24 1999-06-07 Lipid-dispersed solution, production thereof and use in determining lipid levels

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/641,765 Ceased US5759445A (en) 1995-05-24 1996-05-02 Lipid-dispersed solution and process for producing the same

Country Status (4)

Country Link
US (2) US5759445A (en)
EP (1) EP0744621B1 (en)
CN (1) CN1088195C (en)
DE (1) DE69632100T2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10228680A1 (en) * 2002-06-27 2004-01-22 Holden Development Limited, Tortola Basis for transdermal formulations (PTF)
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
ATE521355T1 (en) 2004-05-19 2011-09-15 Los Angeles Biomed Res Inst USE OF A DETERGENT FOR NON-SURGICAL FAT REMOVAL
TWI467702B (en) * 2005-03-28 2015-01-01 Semiconductor Energy Lab Memory device and manufacturing method the same
GB0522942D0 (en) 2005-11-10 2005-12-21 Leigh Steven Dissolution composition
WO2008040799A2 (en) * 2006-10-06 2008-04-10 Boehringer Ingelheim International Gmbh Process for preparing instant forms of aqueous mixed micellar solutions as physiological buffer systems for use in the analysis of in vitro release
CN101762709B (en) * 2008-12-19 2013-06-12 深圳迈瑞生物医疗电子股份有限公司 Cholesterol water quality calibration solution and preparation method
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
RU2682249C2 (en) * 2012-05-31 2019-03-18 Терумо Кабусики Кайся Ph-sensitive carrier and method for production thereof, ph-sensitive medicine and ph-sensitive pharmaceutical composition each containing said carrier, and culture method using said ph-sensitive medicine or said ph-sensitive pharmaceutical composition
US20160074422A1 (en) * 2013-05-08 2016-03-17 Northeastern University Mucus strengthening formulations to alter mucus barrier properties

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2062782A (en) * 1936-01-10 1936-12-01 Albert K Epstein Treatment of lecithin
US2362013A (en) * 1940-05-07 1944-11-07 Winthrop Chem Co Inc Stable colloidal solutions containing lecithin and cholesterol and process of preparing same
US3361680A (en) * 1963-05-13 1968-01-02 Sun Oil Co Use of ultrasonic vibrations to disperse a liquid in another liquid
US3505074A (en) * 1967-04-18 1970-04-07 Lever Brothers Ltd Phosphatides and their method for their preparation
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
US4158707A (en) * 1976-07-12 1979-06-19 Hoffmann-La Roche Inc. Parenteral preparations
US4200551A (en) * 1978-11-27 1980-04-29 A. E. Staley Manufacturing Company Cold-water-dispersible lecithin concentrates
US4289649A (en) * 1978-09-11 1981-09-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Aqueous lipid standard solution
US4290774A (en) * 1980-01-07 1981-09-22 Miles Laboratories, Inc. Purification of lipoprotein cholesterol for use as a cholesterol reference material
JPS5784356A (en) * 1980-11-13 1982-05-26 Toyobo Co Ltd Water soluble standard solution for measurement of fatty substance
US4343897A (en) * 1979-02-05 1982-08-10 Boehringer Mannheim Gmbh Reagent for the determination of lipase and process for preparing same
US4409326A (en) * 1980-07-10 1983-10-11 Modrovich Ivan Endre Stabilized enzymatic solutions and method for determining total cholesterol in human serum
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2062782A (en) * 1936-01-10 1936-12-01 Albert K Epstein Treatment of lecithin
US2362013A (en) * 1940-05-07 1944-11-07 Winthrop Chem Co Inc Stable colloidal solutions containing lecithin and cholesterol and process of preparing same
US3361680A (en) * 1963-05-13 1968-01-02 Sun Oil Co Use of ultrasonic vibrations to disperse a liquid in another liquid
US3505074A (en) * 1967-04-18 1970-04-07 Lever Brothers Ltd Phosphatides and their method for their preparation
US4115313A (en) * 1974-10-08 1978-09-19 Irving Lyon Bile acid emulsions
US4158707A (en) * 1976-07-12 1979-06-19 Hoffmann-La Roche Inc. Parenteral preparations
US4289649A (en) * 1978-09-11 1981-09-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Aqueous lipid standard solution
US4200551A (en) * 1978-11-27 1980-04-29 A. E. Staley Manufacturing Company Cold-water-dispersible lecithin concentrates
US4343897A (en) * 1979-02-05 1982-08-10 Boehringer Mannheim Gmbh Reagent for the determination of lipase and process for preparing same
US4290774A (en) * 1980-01-07 1981-09-22 Miles Laboratories, Inc. Purification of lipoprotein cholesterol for use as a cholesterol reference material
US4409326A (en) * 1980-07-10 1983-10-11 Modrovich Ivan Endre Stabilized enzymatic solutions and method for determining total cholesterol in human serum
JPS5784356A (en) * 1980-11-13 1982-05-26 Toyobo Co Ltd Water soluble standard solution for measurement of fatty substance
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)

Also Published As

Publication number Publication date
US5759445A (en) 1998-06-02
DE69632100T2 (en) 2005-04-28
CN1088195C (en) 2002-07-24
EP0744621B1 (en) 2004-04-07
EP0744621A2 (en) 1996-11-27
CN1146018A (en) 1997-03-26
DE69632100D1 (en) 2004-05-13
EP0744621A3 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
USRE37002E (en) Lipid-dispersed solution, production thereof and use in determining lipid levels
US4921706A (en) Unilamellar lipid vesicles and method for their formation
Robinson The chemical composition of chylomicra in the rat
Boelsterli et al. Modulation by S–Adenosyl–L–Methionine of Hepatic Na+, K+–Atpase, Membrane Fluidity, and Bile Flow in Rats With Ethinyl Estradiol–Induced Cholestasis
Armand et al. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum
Cheng et al. The role of cholesterol in the activity of reconstituted Ca-ATPase vesicles containing unsaturated phosphatidylethanolamine.
Shinitzky et al. Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate
Bryszewska et al. Changes in fluidity and composition of erythrocyte membranes and in composition of plasma lipids in type I diabetes
Bazzi et al. Association of protein kinase C with phospholipid monolayers: two-stage irreversible binding
Gheriani-Gruszka et al. Hydrolysis of phosphatidylcholine in phosphatidylcholine-cholate mixtures by porcine pancreatic phospholipase A2.
Bhamidipati et al. Interactions of lyso 1-palmitoylphosphatidylcholine with phospholipids: a 13C and 31P NMR study
Marsh et al. Protein-immobilized lipid in dimyristoylphosphatidylcholine-substituted cytochrome oxidase: evidence for both boundary and trapped-bilayer lipid
Spooner et al. Effect of free cholesterol on incorporation of triolein in phospholipid bilayers
Nishida et al. Disruption of low-and high-density human plasma lipoproteins and phospholipid dispersions by 1-anilinonaphthalene-8-sulfonate
Bhat et al. Enzymatic synthesis/hydrolysis of cholesteryl oleate in surface films. Inhibition by lecithin and its reversal by bile salts.
Fitzharris et al. Hydrolysis of guinea pig nascent very low density lipoproteins catalyzed by lipoprotein lipase: activation by hjman apolipoprotein C-II.
Hui et al. Binding of plasma low density lipoproteins to erythrocytes
Sergeeva et al. A Glucose‐Responsive Polymer Nanocarrier Based on Sulfonated Resorcinarene for Controlled Insulin Delivery
Jououanel et al. A rapid and sensitive fluorometric assay of serum phospholipid
Lairon et al. The influence of bile salts and bile lipoprotein complex on pancreatic lipase hydrolysis of monomolecular films
JP3173994B2 (en) Lipid dispersion and method for producing the same
Aozaki Decreased membrane fluidity in erythrocytes from patients with Crohn’s disease
US5491093A (en) Quantitative determination of lipid, and of co-existing two compounds
Nakagawa et al. Effect of organophosphate pesticides on lecithin-cholesterol acyltransferase in human plasma
Salmon et al. Magic-angle spinning and solution 13C nuclear magnetic resonance studies of medium-and long-chain cholesteryl esters in model bilayers

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees